Nanoparticles based on PLGA and its co‐polymer: An overview

MS Muthu


Poly (D, L-lactide-co-glycolide) (PLGA) is approved by the Food and Drug Administration for drug delivery use. The polymeric nanoparticles based on PLGA and its co-polymer are designed for controlled and targeted drug delivery. Also,
PLGA and its co-polymer are important in designing nanoparticles with desired characteristics such as biocompatibility, biodegradation, particle size, surface properties, drug release and targetability.This review focuses on the polymer literature, methods for preparation of nanoparticles and recent studies on the nanoparticles based on PLGA and its co-polymer for the
conventional and targeted delivery of drugs by various routes.

Full Text:



Allemann E, Gurny R, Doelker E. Drug-loaded nanoparticles-prepa

ration methods and drug targeting issues. Eur J Pharm Biopharm


Muthu MS, Singh S. Targeted nanomedicines: Effective treatment

modalities for cancer, AIDS and brain disorders. Nanomed 2009;4:105‐18.

Labhasetwar V, Song C, Levy RJ. Nanoparticles drug delivery systems.

Adv Drug Deliv Rev 1997;24:63-85.

Stevanović M, Savić J, Jordović B, Uskoković D. Fabrication, in vitro

degradation and the release behaviours of poly(DL-lactide-co-glycolide)

nanospheres containing ascorbic acid. Colloids Surf B Biointerfaces


Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I.

Methods for preparation of drug-loaded polymeric nanoparticles.

Nanomedicine 2006;2:8-21.

Verger ML, Fluckiger L, Kim Y, Hoffman M, Maincent P. Preparation and

characterization of nanoparticles containing an antihypertensive agent.

Eur J Pharm Biopharm 1998;46:137-43.

Mainardes RM, Evangelista RC. PLGA nanoparticles containing

praziquantel: Effect of formulation variables on size distribution. Int J

Pharm 2005;290:137-44.

Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery

and targeting. Curr Opin Sol State Mater Sci 2002;6:319-27.

Zhao Y, Chen W, Cai Q, Wang S, Bo J, Wu C. Erosion induced controllable

release of gliclazide encapsulated inside degradable polymeric

particles. Macromol Biosci 2004;4:308-13.

Lewis DD. Controlled release of bioactive agents from lactide/glycolide

polyiners. In: Chasin M, Langer R, eds. Biodegradable Polymers as Drug

Delivery Systems. New York, Marcel Dekker; 1990. p. 1-41.

Gilding DK, Reed AM. Biodegradable polymers for use in surgery.

Polyglycolic/poly(lactic acid) homo- and copolymers: 1. Polymer


Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity,

biocompatibility and clinical applications of polylactic acid/polyglycolic

acid copolymers. Biomaterials 1996;17:93-102.

Ravivarapu HB, Burton K, DeLuca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm 2000;50:263-70.

Li S, McCarthy SP. Influence of crystallinity and stereochemistry

on the enzymatic degradation of poly(lactide)s. Macromolecules


Schliecker G, Schmidt C, Fuchs S, Kissel T. Characterization of a

homologous series of D,L-lactic acid oligomers; a mechanistic study

on the degradation kinetics in vitro. Biomaterials 2003;24:3835-44.

Park TG. Degradation of poly(D,L-lactic acid) microspheres: Effect of

molecular weight. J Control Release 1994;30:161-73.

Vert M. Aliphatic polyesters: Great degradable polymers that cannot

do everything. Biomacromolecules 2005;6:538-46.

Makino K, Arakawa M, Kondo T. Preparation and in vitro degradation

properties of polylactide microcapsules. Chem Pharm Bull 1985;33:


Göpferich A. Mechanisms of polymer degradation and erosion.

Biomaterials 1996;42:1-11.

Visscher GE, Pearson JE, Fong JW, Argentieri GJ, Robison RL, Maulding

HV. Effect of particle size on the in vitro and in vivo degradation rates

of poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res


Anderson JM. In vivo biocompatibility of implantation delivery systems

and biomaterials. Eur J Pharm Biopharm 1994;40:1-8.

Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, Argentieri GJ.

Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-

glycolide) microcapsules. J Biomed Mater Res 1985;19:349‐65.

Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE,

Argentieri GJ. Biodegradation of and tissue reaction to poly(DL-lactide)

microcapsules. J Biomed Mater Res 1986;20:667-76.

Ziats NP, Miller KM, Anderson JM. In vivo and in vitro interaction of cells

with biomaterials. Biomaterials 1988;9:5-3.

Ward PA. Recruitment of inflammatory cells into lung: Roles of

cytokines, adhesion molecules, and complement. J Lab Clin Med


Comets E, Mentré F, Kawai R, Nimmerfall F, Marbach P, Vonderscher J.

Modeling the kinetics of release of octreotide from long-acting

formulations injected intramuscularly in rabbits. J Pharm Sci


Julienne MC, Alonso MJ, Gomez Amoza JL, Benoit JP. Preparation of

poly(DL-lactide/glycolide) nanoparticles of controlled particle size

distribution: Application of experimental designs. Drug Dev Ind Pharm


Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles

containing doxorubicin-PLGA conjugate for sustained release. Pharm

Res 1999;16:1114-18.

Allémann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release

properties of drug-loaded poly(DL-lactic acid) nanoparticles produced

by a salting-out procedure. Pharm Res 1993;10:1732-37.

Fessi H, Puisieux F, Devissaguet JP. Process for the preparation of

dispersible colloidal systems of a substance in the form of nanoparticles.

United States Patent 1992;5:118-528.

Jung T, Breitenbach A, Kissel T. Sulfobutylated poly(vinyl alcohol)-graft-

poly(lactide-co-glycolide)s facilitate the preparation of small negatively

charged biodegradable nanospheres. J Control Release 2000;67:157-69.

Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K.

Preparation, characterisation and maintenance of drug efficacy of

doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J

Pharm 2007;341:207-14.

Piñón-Segundo E, Ganem-Quintanar A, Alonso-Pérez V, Quintanar‐

Guerrero D. Preparation and characterization of triclosan nanoparticles

for periodontal treatment. Int J Pharm 2005;294:217-32.

Dong Y, Feng SS. Poly(d,l-lactide-co-glycolide)/montmorillonite

nanoparticles for oral delivery of anticancer drugs. Biomaterials


Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Ravi Kumar MN.

Sustained release nanoparticulate formulation containing antioxidant-

ellagic acid as potential prophylaxis system for oral administration.

J Drug Target 2006;14:27-34.

Pandey R, Khuller GK. Nanoparticle-based oral drug delivery system

for an injectable antibiotic - streptomycin. Evaluation in a murine

tuberculosis model. Chemotherapy 2007;53:437-41.

Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. Estradiol loaded

PLGA nanoparticles for oral administration: Effect of polymer molecular

weight and copolymer composition on release behavior in vitro and

in vivo. J Control Release 2007;119:77-85.

Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nanoparticles

for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic

studies in comparison to Sandimmune Neoral. J Control Release


Lecaroz MC, Blanco-Prieto MJ, Campanero MA, Salman H, Gamazo C.

Poly(D,L-lactide-coglycolide) particles containing gentamicin:

Pharmacokinetics and pharmacodynamics in Brucella melitensis-

infected mice. Antimicrob Agents Chemotherr 2007;51:1185-90.

Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle

formulations of risperidone: Preparation and neuropharmacological

evaluation. Nanomedicine 2009;5:323-33.

Davaran S, Rashidi MR, Pourabbas B, Dadashzadeh M, Haghshenas

NM. Adriamycin release from poly(lactide-coglycolide)-polyethylene

glycol nanoparticles: Synthesis, and in vitro characterization. Int J

Nanomedicine 2006;1:535-9.

Choi SW, Kim JH. Design of surface-modified poly(D,L-lactide-co-

glycolide) nanoparticles for targeted drug delivery to bone. J Control

Release 2007;122:24-30.

Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K.

In vivo investigation of tolerance and antitumor activity of cisplatin-

loaded PLGA-mPEG nanoparticles. Eur J Pharm Biopharm 2007;71:190‐95.

Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles

and their applications in medicine. Nanomed 2006;1:157-68.

Ngaboni Okassa L, Marchais H, Douziech-Eyrolles L, Cohen-Jonathan S,

Soucé M, Dubois P, et al. Development and characterization of

sub‐micron poly(D,L-lactide-co-glycolide) particles loaded with

magnetite/maghemite nanoparticles. Int J Pharm 2005;302:187-96.

Jones M, Leroux J. Polymeric micelles - a new generation of colloidal

drug carriers. Eur J Pharm Biopharm 1999;48:101-11.

Yoo HS, Park TG. Biodegradable polymeric micelles composed of

doxorubicin conjugated PLGA-PEG block copolymer. J Control Release




  • There are currently no refbacks.